CAM
MRNA icon

Cresset Asset Management’s Moderna MRNA Stock Holding History

Cresset Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
28,359
+10,116
+55% +$523K 0.01% 674
2026
Q1 		$927K Buy
18,243
+644
+4% +$30K ﹤0.01% 812
2025
Q4 		$519K Buy
17,599
+2,673
+18% +$72.6K ﹤0.01% 1049
2025
Q3 		$386K Buy
14,926
+55
+0.4% +$1.53K ﹤0.01% 1150
2025
Q2 		$410K Sell
14,871
-3,549
-19% -$93.5K ﹤0.01% 1004
2025
Q1 		$522K Buy
+18,420
New +$654K ﹤0.01% 1047
2024
Q4 		– Sell
-31,205
Closed -$2.09M – 2041
2024
Q3 		$2.09M Buy
31,205
+6,571
+27% +$603K 0.01% 792
2024
Q2 		$2.93M Buy
24,634
+2,478
+11% +$314K 0.01% 574
2024
Q1 		$2.36M Buy
22,156
+6,127
+38% +$618K 0.01% 576
2023
Q4 		$1.59M Buy
16,029
+1,027
+7% +$86.4K 0.01% 686
2023
Q3 		$1.55M Sell
15,002
-1,011
-6% -$113K 0.01% 659
2023
Q2 		$1.95M Buy
+16,013
New +$2.14M ﹤0.01% 657
2022
Q2 		– Sell
-2,118
Closed -$365K – 1039
2022
Q1 		$365K Sell
2,118
-408
-16% -$68.7K ﹤0.01% 709
2021
Q4 		$642K Sell
2,526
-43
-2% -$12.6K 0.01% 609
2021
Q3 		$989K Buy
+2,569
New +$947K 0.01% 394

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Cresset Asset Management's MRNA Position: Q2 2026 in Review

Cresset Asset Management increased its Moderna (MRNA) stake by 55% in Q2 2026, buying an estimated $523K and bringing the position to 28,359 shares worth $1.99M. The position accounts for 0.01% of the portfolio, ranked #674.

Cresset Asset Management first reported a position in MRNA in Q3 2021 and has held it in 15 quarters since. The position peaked at $2.93M in Q2 2024. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Cresset Asset Management held 28,359 shares of Moderna worth $1.99M as of Q2 2026.
  • Cresset Asset Management bought 10,116 Moderna shares in Q2 2026, an estimated $523K.
  • Moderna made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #674 holding.
  • Cresset Asset Management first reported a position in Moderna in Q3 2021 and has held it in 15 quarters since.
  • Cresset Asset Management's Moderna position peaked at $2.93M in Q2 2024.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.